Christopher Stokoe

2.2k total citations
17 papers, 547 citations indexed

About

Christopher Stokoe is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christopher Stokoe has authored 17 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christopher Stokoe's work include Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (7 papers). Christopher Stokoe is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (7 papers). Christopher Stokoe collaborates with scholars based in United States, United Kingdom and Canada. Christopher Stokoe's co-authors include Priya Rastogi, Virginia F. Borges, Louise Provencher, Soonmyung Paik, Jonathan Polikoff, Norman Wolmark, James N. Atkins, Charles E. Geyer, André Robidoux and Timothy D. Moore and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Christopher Stokoe

17 papers receiving 537 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Stokoe United States 9 480 254 189 134 49 17 547
Isabelle Desmoulins France 15 361 0.8× 271 1.1× 191 1.0× 205 1.5× 84 1.7× 75 624
EA Perez United States 11 541 1.1× 172 0.7× 279 1.5× 102 0.8× 162 3.3× 32 617
Hannah Douthwaite Spain 6 717 1.5× 428 1.7× 262 1.4× 190 1.4× 54 1.1× 8 835
Karen Afenjar United States 6 461 1.0× 193 0.8× 168 0.9× 218 1.6× 52 1.1× 15 571
T. Yu United States 6 274 0.6× 132 0.5× 136 0.7× 278 2.1× 29 0.6× 12 495
S. Kahlert Germany 6 445 0.9× 299 1.2× 132 0.7× 138 1.0× 37 0.8× 12 539
Javier Cortes Spain 3 445 0.9× 195 0.8× 209 1.1× 176 1.3× 55 1.1× 4 497
Tanja Badovinac-Črnjević United States 7 418 0.9× 120 0.5× 185 1.0× 161 1.2× 68 1.4× 9 533
R. Lambert-Falls United States 6 544 1.1× 102 0.4× 261 1.4× 98 0.7× 60 1.2× 9 578
Angela Sciandivasci Italy 11 425 0.9× 286 1.1× 85 0.4× 191 1.4× 100 2.0× 23 593

Countries citing papers authored by Christopher Stokoe

Since Specialization
Citations

This map shows the geographic impact of Christopher Stokoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Stokoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Stokoe more than expected).

Fields of papers citing papers by Christopher Stokoe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Stokoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Stokoe. The network helps show where Christopher Stokoe may publish in the future.

Co-authorship network of co-authors of Christopher Stokoe

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Stokoe. A scholar is included among the top collaborators of Christopher Stokoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Stokoe. Christopher Stokoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Kruse, Megan, Irene Kang, Nusayba A. Bagegni, et al.. (2021). Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncology and Therapy. 10(1). 279–289. 4 indexed citations
2.
Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations
3.
4.
O’Shaughnessy, Joyce, Hartmut Koeppen, Yuanyuan Xiao, et al.. (2015). Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research. 21(19). 4305–4311. 37 indexed citations
5.
Paul, Devchand, Scot Sedlacek, Anne Favret, et al.. (2013). Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. The Lancet Oncology. 14(11). 1121–1128. 92 indexed citations
6.
O’Shaughnessy, Joyce, David Loesch, Devchand Paul, et al.. (2013). ER as a predictor of early breast cancer (EBC) outcomes in patients.. Journal of Clinical Oncology. 31(15_suppl). 590–590. 1 indexed citations
7.
O’Shaughnessy, Joyce, John Pippen, Devchand Paul, et al.. (2012). Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.. Journal of Clinical Oncology. 30(15_suppl). 547–547. 3 indexed citations
8.
Jones, SE, D Paul, Ruth Oratz, et al.. (2011). PD07-03: Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab (HER TC) in HER2−Positive Early Stage Breast Cancer Patients.. Cancer Research. 71(24_Supplement). PD07–3. 2 indexed citations
9.
Pippen, John, Devchand Paul, Christopher Stokoe, et al.. (2011). Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.. Journal of Clinical Oncology. 29(15_suppl). 500–500. 9 indexed citations
10.
Sedlacek, Scot, S. Vukelja, Christopher Stokoe, et al.. (2011). P5-18-09: The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim.. Cancer Research. 71(24_Supplement). P5–18. 2 indexed citations
11.
Pippen, John, Anthony Elias, Marcus A. Neubauer, et al.. (2010). A Phase II Trial of Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer Who Have Received Prior Taxane Therapy. Clinical Breast Cancer. 10(2). 148–153. 10 indexed citations
12.
13.
Pippen, John, J. O’Shaughnessy, Christopher Stokoe, et al.. (2009). 0151 Adjuvant dose-dense adriamycin plus cytoxan followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: A pilot study. The Breast. 18. S57–S57. 1 indexed citations
14.
Stokoe, Christopher. (2009). Adapting Practice in the Face of New Data. Journal of Oncology Practice. 5(2). 83–85. 1 indexed citations
15.
Jones, Stephen E., Christopher Stokoe, Mark D. Sborov, et al.. (2008). The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer. Clinical Breast Cancer. 8(6). 527–532. 20 indexed citations
16.
Stokoe, Christopher, Michael Oakes, & John Tait. (2003). Word sense disambiguation in information retrieval revisited. 13 indexed citations
17.
Stokoe, Christopher, et al.. (2001). Activity of Infusional Etoposide, Vincristine, and Doxorubicin with Bolus Cyclophosphamide (EPOCH) in Relapsed Hodgkin's Disease. The Oncologist. 6(5). 428–434. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabelle Desmoulins Breakdown of academic impact, for papers by EA Perez Breakdown of academic impact, for papers by Hannah Douthwaite Breakdown of academic impact, for papers by Karen Afenjar Breakdown of academic impact, for papers by T. Yu Breakdown of academic impact, for papers by S. Kahlert Breakdown of academic impact, for papers by Javier Cortes Breakdown of academic impact, for papers by Tanja Badovinac-Črnjević Breakdown of academic impact, for papers by R. Lambert-Falls Breakdown of academic impact, for papers by Angela Sciandivasci
Rankless by CCL
2026